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cental responses to them is key to understanding the pathol-
ogy of both fetal growth restriction and macrosomia. The 
overall effects of the maternal environment on the placenta 
are the product of its exposures throughout gestation, the 
‘placental exposome’. Understanding these environmental 
influences is important as exposures early in gestation, for 
instance causing changes in the function of genes involved 
in nutrient transfer, may determine how the placenta will 
respond to exposures later in gestation, such as to raised ma-
ternal plasma glucose or lipid concentrations. Longitudinal 
studies are required which allow investigation of the influ-
ences on the placenta across gestation. These studies need 
to make full use of developing technologies characterising 
placental function, fetal growth and body composition. Un-
derstanding these processes will assist in the development 
of preventive strategies and treatments to optimise prenatal 
growth in those pregnancies at risk of either excess or insuf-
ficient nutrient supply and could also reduce the risk of 
chronic disease in later life.  © 2013 S. Karger AG, Basel 
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 Abstract 
 Offspring of obese and diabetic mothers are at increased 
risk of being born with excess adiposity as a consequence of 
their intrauterine environment. Excessive fetal fat accretion 
reflects additional placental nutrient transfer, suggesting an 
effect of the maternal environment on placental function. 
High plasma levels of particular nutrients in obese and dia-
betic mothers are likely to be the important drivers of nutri-
ent transfer to the fetus, resulting in excess fat accretion. 
However, not all offspring of obese and diabetic mothers are 
born large for gestational age and the explanation may in-
volve the regulation of placental nutrient transfer required 
for fetal growth. The placenta integrates maternal and fetal 
signals across gestation in order to determine nutrient trans-
fer rate. Understanding the nature of these signals and pla-
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 Introduction 
 Maternal obesity and diabetes alter the intrauterine 
environment and increase the risk of large for gestational 
age (LGA) offspring. A disproportionate increase in fat 
mass makes an important contribution to the increased 
birth weight in LGA babies  [1, 2] , but can also be found 
in offspring born with weight appropriate for their gesta-
tional age  [3] . Excess fetal fat accumulation may predis-
pose these individuals to develop obesity in later life and 
raises the possibility of an intergenerational cycle of obe-
sity  [4] . Maternal obesity is associated with a doubling in 
the rate of LGA births compared to women of normal 
weight  [5] . While shared genetics and environment will 
contribute to this relationship it is likely that factors spe-
cific to the in utero environment are also important. The 
role of intrauterine environment is illustrated by the ob-
servation that babies born to women following bariatric 
surgery have half the risk of becoming obese relative to 
their siblings born prior to surgery  [6] .
 While the association between in utero environment 
and fetal adiposity is clear, with maternal pre-gravid obe-
sity and diabetes being the strongest maternal determi-
nants  [1, 7] , the mechanisms through which maternal fac-
tors increase fetal adiposity are not fully understood. How-
ever, as the principal organ through which nutrients are 
transferred to the fetus, the placenta is likely to be an im-
portant mediator of this process. The placenta is not sim-
ply a passive conduit for nutrients but responds to both 
maternal and fetal signals, altering placental transport and 
metabolic function  [8, 9] . At any point in gestation, placen-
tal function will reflect a progressive accumulation of ex-
ternal influences experienced during the course of its de-
velopment. These can be conceptualised as the ‘placental 
exposome’. The exposome of an individual encompasses 
the product of lifetime environmental exposures starting 
in utero and varying according to life stage  [10] . The in 
utero environment experienced by the placenta is itself the 
product of the maternal exposome, for instance effects of 
maternal obesity on the placenta reflect a historical mis-
match between food intake and energy expenditure.
 Ideally, prevention of obesity and diabetes should occur 
prior to pregnancy. However, where this is not possible, the 
development of successful interventions will be facilitated 
by a more detailed understanding of those pregnancies in 
which maternal obesity and diabetes leads to increased pla-
cental nutrient transfer and greater fetal adiposity.
 This review is based on discussions at the workshop 
‘The Placenta and Its Role for Fetal and Neonatal Devel-
opment’, which took place in Austria, October 2012, sup-
ported by the EU FP7 project EarlyNutrition. Themes 
emerging from this workshop included: the central role 
of placental function in determining fetal growth and 
body composition, how placental function is determined 
by its exposome, the potential for epigenetics to act as a 
mediator of environmental influence on placental func-
tion, and ways in which new technologies can be incor-
porated into longitudinal population studies to investi-
gate the role of the placenta in mediating maternal expo-
sures on fetal growth and postnatal health.
 Placental Structure, Function and Regulation 
 Placental nutrient transfer underpins fetal growth and 
development. The nutrient transfer capacity of a placenta 
will depend on its structure and fetal maternal blood flow, 
whereas actual transfer depends on how these factors and 
transporter density are regulated. This regulation can oc-
cur over long (e.g. structural or epigenetic changes in the 
placenta) and short (e.g. placental responses to maternal 
hormones or nutrients) time scales, and therefore it is im-
portant to understand all the determinants of placental 
function across gestation.
 The growing fetus requires adequate and appropriate 
placental nutrient transfer but excessive nutrient transfer, 
or an inappropriate balance of nutrients, may cause the 
fetus to lay down excess fat and become LGA  [1, 2] . In 
order to identify abnormal fetal growth, it is important to 
understand placental development, the mechanisms un-
derlying placental function and their regulation.
 The placenta has a complex anatomical structure 
which develops throughout gestation increasing its nutri-
ent transfer capacity to match the requirements of the 
growing fetus  [11] . The placental villi are the sites of nu-
trient exchange and, in broad terms, they form in the first 
trimester, branch in the second and assume their final 
structure during the third trimester. Once its final struc-
ture is established, the placenta remains a dynamic organ 
with continual turnover of villous trophoblasts as well as 
development and regression of placental vessels ( fig. 1 ). 
This evolution throughout gestation means that disrup-
tive factors can have persistent effects that will differ de-
pending on their timing. The role of extravillous tropho-
blast cells, which associate with spiral arteries and uterine 
glands, is also important in mediating blood flow to the 
fetus  [12] . Placental weight is a major determinant of fetal 
growth, reflecting a greater nutrient transport capacity. 
Maternal weight gain in early pregnancy has an influence 
on fetal weight, which is thought to be partly mediated 
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through its effects on placental growth  [13] . Consequent-
ly, in some obese mothers, enhanced fetal growth could 
be mediated through raised placental mass  [14] . Blood 
flow through the maternal side of the placenta starts at the 
end of the first trimester. Prior to the initiation of placen-
tal blood flow, the villi are nourished by secretions from 
uterine glands and plasma filtrate  [15] . Maternal blood 
delivers nutrients and oxygen to the placenta and any dis-
ruption of this flow may affect fetal nutrient supply. One 
of the major causes of impaired maternal blood supply is 
the failure of spiral artery remodelling  [16] . Reduced 
blood flow through the placenta as a result of failure to 
remodel the spiral arteries may decrease nutrient avail-
ability to the fetus and may affect fetal development in the 
second and third trimesters  [17] . Failure to remodel the 
spiral arteries early in gestation may therefore limit pla-
cental nutrient transfer capacity throughout gestation.
 Excess placental transfer of glucose and lipids are prime 
candidates for promoting fetal adiposity. Transfer of glu-
cose, lipids and amino acids across the placenta requires 
transport across a series of cell membranes by specific 
membrane transport proteins. Transport occurs across 
the maternal-facing microvillus membrane (MVM) and 
fetal-facing basal membrane (BM) of the placental syncy-
tiotrophoblast ( fig.  1 ). Glucose transfer is primarily 
through facilitated diffusion and is mediated by one fam-
ily of transporters, the GLUTs, across both the MVM and 
the BM. There are multiple transporters for fatty acids and 
amino acids which are differentially localised to the MVM 
and BM  [18] . Once across the BM, it is likely that glucose 
and amino acids can diffuse through endothelial junctions 
into the fetal circulation while fatty acids may also require 
mediated transport across the endothelium.
 Metabolism of nutrients within the syncytiotropho-
blast will affect fetal transfer and may be regulatory  [19] . 
A proportion of the glucose taken up by the placenta is 
converted to lactate and in humans this lactate is primar-
ily transported back to the mother  [20] . Fatty acids and 
amino acids can be incorporated into lipid and protein 
pools, respectively, as well as being catabolised for energy.
 Fig. 1. Representation of the structures of a 
first-trimester immature intermediate vil-
lus ( a ,  b ) and a third-trimester terminal vil-
lus ( c ,  d ).  a ,  b There is a double-layered 
epithelium with a thick syncytiotropho-
blast (ST) and a complete layer of cytotro-
phoblasts (CT). The distance between a 
capillary (Ca) and the outer surface of the 
ST is depicted by an arrow and is in the 
range of 50–60 μm at the beginning of 
pregnancy.  c ,  d There is only a thin layer 
of ST with some CT underneath. Especially 
in terminal villi, Ca transform into larger 
sinusoids that are located subjacent to the 
ST. Hence, the distance between fetal 
and maternal blood – as depicted by the ar-
rows – is very short (1.3–4 μm). The short-
ening of the diffusion distance between the 
maternal and fetal circulation during the 
course of pregnancy facilitates the trans-
port of nutrients and oxygen paralleling the 
increasing needs of the growing fetus. The 
MVM and BM of the ST are indicated by 
arrows. 
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 Membrane transporter abundance in the placenta is 
regulated in response to nutritional and endocrine signals 
from the mother  [21] . Both maternal diet and body com-
position are associated with changes in placental trans-
porter activity that reflect nutritional and endocrine sig-
nals  [22, 23] . Decreased transporter activity is associated 
with fetal growth restriction that precedes the onset of 
intra-uterine growth retardation  [24] . Changes in the 
pattern of expression and methylation of the different 
GLUT transporters in the placenta point to dynamic reg-
ulation across gestation  [25] .
 For amino acid transport, and most likely for other 
nutrients as well, a change in the activity of one trans-
porter cannot be assumed to correspond to an equivalent 
change in nutrient transport  [26] . Computational model-
ling of these processes may provide an important tool to 
better understand these processes and to identify the rate-
limiting steps, as these will be the best targets for thera-
peutic interventions  [26, 27] .
 In some diabetic or obese woman, elevated nutrient 
levels may drive placental transfer down the concentration 
gradient thereby promoting fetal growth. However, in 
many obese and diabetic pregnancies, fetal growth is nor-
mal raising the question as to why fetal overgrowth occurs 
in some pregnancies but not in others. One explanation 
may be that maternal obesity and diabetes in themselves 
are not sufficient to induce fetal obesity, but that addition-
al exposures are necessary, which in combination lead to 
excessive placental nutrient transfer and LGA offspring.
 The Placental Exposome and Placental Function 
 For a fetus to become LGA there must be an underly-
ing placental capacity able to support this growth. In ab-
solute terms, fetal growth is greatest in the last trimester 
and this is when placental nutrient transfer must be suf-
ficient. As placental function develops progressively, it 
must acquire this capacity much earlier in gestation. For 
this reason, environmental exposure affecting the placen-
ta in early gestation may interact with those acting in late 
gestation in order to determine the fetal growth outcome 
( fig. 2 ). For instance, an early exposure leading to a large 
placenta may, when coupled with a later nutrient-rich en-
vironment, increase the likelihood of an LGA baby (but 
may decrease the likelihood of fetal growth restriction in 
a nutrient-poor late-gestation environment). Alterna-
tively, an early exposure which causes down-regulation of 
glucose transporters could reduce the likelihood of an 
LGA infant when exposed to a later glucose-rich environ-
ment (but might increase the likelihood of fetal growth 
restriction in a lower glucose environment).
 Studies linking maternal body composition to placen-
tal function and gene expression suggest a role for longer-
term, pre-pregnancy influences of maternal diet on the 
placenta although it is not clear at which point in gesta-
tion these act  [22, 23, 28] . Environmental exposures dur-
ing gametogenesis could influence placental develop-
ment and thus should be considered as part of the placen-
tal exposome  [29] .
Pla
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 Fig. 2. Placental development and function is determined by the prod-
uct of its environmental exposures across gestation. This will deter-
mine how big the fetus grows and whether its body composition is 
balanced or imbalanced. Normally grown babies (AGA) as well as 
some small (SGA) or large (LGA) babies may have a balanced body 
composition, but most have either inappropriately low or high adi-
posity, respectively. Abnormally small (IUGR/FGR) infants may have 
a decreased fat mass, while abnormally large infants with fetal growth 
excess or fetal growth surplus (FGE/FGS) can have an increased fat 
mass. Both extremes of fetal growth may lead to adult adiposity. 
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 From an evolutionary perspective, co-adaptation sug-
gests that genes will be selected that promote signalling 
between the mother and offspring to optimise nutrient 
partitioning in a given environment  [30] . In our evolu-
tionary past, under- rather than over-nutrition will have 
been the predominant selective pressure on the placenta. 
In this case, signalling between the mother and the fetus 
via the placenta may be poorly adapted to protect the fe-
tus where there is an overabundance of maternal nutri-
ents such as in maternal obesity or diabetes  [31] .
 A Role for Epigenetics in Pregnancy Adaptation and 
Placental Function? 
 Epigenetic mechanisms encompass a range of covalent 
and other modifications to DNA and associated proteins 
that together regulate gene activity. The epigenetic profile 
(epigenome) is dynamic in early life and sensitive to en-
vironmental influences, yet the role of epigenetic varia-
tion in regulating placental function and pregnancy out-
come in humans remains unclear. Epigenetic chance in 
response to an in utero environmental exposure may 
manifest as an alteration in placental development poten-
tially as an ‘adaptation’ of the developing pregnancy to a 
‘perceived’ postnatal environment related to the in utero 
exposure.
 Epigenetic changes are therefore likely to be an impor-
tant mechanism by which early exposure affects placental 
function in gestation. There is evidence for increased in-
ter-individual variation in the DNA methylation profile 
in the third-trimester placenta relative to first and second 
trimesters, supporting an accumulation of environmen-
tally induced changes in DNA methylation patterns  [32] . 
The mechanisms underlying this variation remain un-
clear, as does the potential link between altered methyla-
tion and adverse pregnancy outcomes. However, parallel 
changes in methylation and expression in glucose trans-
porters across gestation support a functional role for epi-
genetic regulation in the placenta  [25] .
 Maternal Determinants of Placental Function 
 It is currently unclear which aspects of maternal obe-
sity or diabetes predispose to LGA offspring and whether 
there are common or distinct pathways. Obvious candi-
dates include differences in plasma nutrient and meta-
bolic hormone levels, but other factors such as the sys-
temic inflammatory status could also be important.
 The altered energy homeostasis of an obese woman, 
specifically her higher systemic insulin concentrations 
and insulin resistance, may also impact on placental func-
tion. Even though the placenta is not a typical insulin-
sensitive tissue with regard to the stimulation of glucose 
transport, it is equipped with functional insulin receptors 
and downstream signalling molecules  [33] . Leptin is an-
other potentially relevant endocrine signal since plasma 
leptin is elevated in obese and diabetic women and is syn-
thesized in excess by the placenta  [34] .
 Some diabetic and obese pregnant women have chron-
ic low-grade systemic inflammation, which extends to the 
placental tissue  [35] . The source and nature of the inflam-
matory stimuli are currently unknown. However, factors 
originating from the maternal environment are strong 
candidates to enhance inflammation. Increased systemic 
lipopolysaccharides in obese pregnant women support a 
role of innate immune regulation by maternal stimuli in 
increasing inflammation at the maternal-fetal interface 
 [36] . Lipids, particularly saturated fatty acids, can also 
trigger immune responses in the placenta increasing in 
situ inflammation in a manner similar to lipopolysaccha-
rides. The response of the placenta to inflammatory stim-
uli is demonstrated by enhanced production of cytokines 
and inflammatory factors released locally and systemati-
cally in diabetes and obesity  [37] .
 In addition to dietary factors and hormones, chemi-
cals, such as endocrine disruptors, in the maternal envi-
ronment can also change the phenotype of offspring by 
stably altering the epigenome, as has been demonstrated 
in rodents  [38, 39] .
 Postnatal Outcomes 
 The long-term consequences of being born with excess 
fat or LGA are potentially very significant and further re-
search is required to better understand these relation-
ships. Being born large is associated with an increased risk 
of obesity in childhood although the extent to which this 
persists into adulthood has not yet been fully defined  [40] . 
If being born LGA is established to be causally associated 
with adult obesity it might also be expected to predict the 
risk of metabolic disease and in certain populations LGA 
may directly be associated with type-2 diabetes. In most 
populations, the risk of type-2 diabetes decreases with in-
creasing birth weight  [41] , but in those with a high preva-
lence of gestational diabetes, the risk of later diabetes is 
greatest at the highest birth weights  [42] . Further research 
is required to establish whether fetal adiposity contrib-
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utes to the risk of adult adiposity and the associated health 
consequences. This research needs to make use of more 
detailed analysis of body composition at birth to distin-
guish those born with a high proportion of body fat from 
those who are genetically large.
 While the focus of this review has been on LGA babies 
it should not be forgotten that babies who do not reach 
their growth potential in utero are also prone to develop 
obesity and other conditions related to the metabolic syn-
drome in later life which are associated with excess adi-
posity  [43] .
 If fetal adiposity leads to adult adiposity how might 
this be mediated? One mechanism may be through effects 
on the hyperplasia of white, beige or brown adipose tissue 
 [44] . Adipocyte number appears to be a major determi-
nant of adult adiposity and suggests a tight regulation of 
adipocyte cell number during adult life  [45] . Brown fat 
remains active into adult life  [46] and if its abundance was 
determined in utero this would have implications for en-
ergy expenditure and the propensity to develop obesity. 
While the relationship between early environment and 
brown fat mass has not been determined it is interesting 
to note that morbidly obese adults have less brown fat, 
suggesting a role in the development of obesity  [47] .  Oth-
er mechanisms may involve reprogramming of neural ap-
petite control and there is evidence for reprogramming of 
the hypothalamus-pituitary-adrenal axis  [48] . The rela-
tionship between fetal adiposity and early growth should 
also be investigated as there are strong correlates between 
early growth and later obesity  [49] ( fig. 2 ).
 Population Studies and the Power of New 
Technologies 
 Population studies are needed to identify the effects of 
maternal obesity on placental function, fetal growth and 
postnatal consequences. Developing technologies mean 
that the level of insight that can be gained from these 
studies is now substantial. For instance, birth weight is an 
imprecise marker of fetal growth and while some LGA 
babies will have a disproportionate increase in adipose 
tissues others may be proportionately large. If fetal adi-
posity is key to future health then it is those infants with 
disproportionately high adiposity rather than those who 
are proportionately large that need to be identified. The 
use of neonatal dual-energy X-ray absorptiometry and 
densitometry to measure body composition allows us to 
make this distinction and has great potential to enhance 
the power of these studies.
 Furthermore, in order to demonstrate the role of the 
placenta in mediating maternal environment, it is impor-
tant that we are able to make better estimates of placental 
function. It is now possible to make in utero measurements 
of fetal and placental blood flow and growth  [50, 51] . The 
use of stable isotopes provides an important means to 
study placental transfer in vivo avoiding the drawbacks of 
ex vivo systems  [52] when coupled with increasingly pow-
erful biochemical and molecular approaches to study plas-
ma and tissues samples  [25, 53] . An example of the use of 
these techniques in a longitudinal study comes from the 
Southampton Women’s Survey, where fetal growth mea-
sures have been determined by ultrasound and related to 
placental gene expression and post-natal bone density  [54] . 
Other studies have related maternal body composition and 
placental weight to fetal blood flow distribution in the fetus 
 [50, 55] . Increased fetal liver blood flow is associated with 
fetal macrosomia in the third trimester  [51] and greater 
offspring fat mass measured by dual-energy X-ray absorp-
tiometry, both in the infant at birth and at age 4 years  [50] . 
In the Generation R study, analysis of placental haemody-
namics demonstrated associations between maternal life-
style characteristics and placental resistance indices  [56] .
 This review has focused on the consequences of mater-
nal obesity in humans, however, it should not be forgot-
ten that there is a large body of related work in animal 
models, which has been reviewed elsewhere  [57, 58] . 
These animal models provide supporting evidence that 
maternal obesity has long-term effects on the offspring. 
They also allow study of the underlying processes in ways 
that are not always possible in humans  [59, 60] . As such, 
animal models provide an important research tool which 
compliment human studies.
 Conclusion 
 Maternal obesity and diabetes increase the risk of ex-
cessive fat accretion in the offspring and are strong risk 
factors for being born LGA. However, not all such preg-
nancies lead to fetal overgrowth, and understanding why 
some fetuses are protected will assist the characterisation 
of future intervention strategies. Increased nutrient trans-
fer is required to produce an LGA infant, and the factors 
which determine whether or not placental function medi-
ates this nutrient transfer will determine how the fetus 
grows. We suggest that to understand this problem will 
require an appreciation of how exposures across develop-
ment may affect placental function and that this should 
be a focus of new and ongoing longitudinal studies.
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